Recently, there has been considerable discussion regarding the classif
ication of drugs as a function of their therapeutic index, defined as
the ratio between the upper and lower limits of the therapeutic range.
Pharmacologic agents with a therapeutic index <2 are classified as ''
narrow therapeutic index'' (NTI) drugs, One of the agents classified a
s an NTI drug is carbamazepine. These recent developments led us to ev
aluate critically the evidence supporting the classification of carbam
azepine as an NTI drug to address an old question: ''Does carbamazepin
e have a narrow therapeutic plasma concentration range?''